Bristol Myers Squibb (CGT Mfg) vs Eurofins CDMO: CDMO Comparison
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificates; Eurofins CDMO does not appear in EudraGMDP.
- Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; Eurofins CDMO does not.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (577 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO qualify as Cell Therapy manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs Eurofins CDMO
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or Eurofins CDMO?
Both Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 5 FDA inspections on record; Eurofins CDMO has 4.
How do Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. Eurofins CDMO holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or Eurofins CDMO?
Bristol Myers Squibb (CGT Mfg) is matched to 577 ClinicalTrials.gov records as a manufacturing partner; Eurofins CDMO is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Bristol Myers Squibb (CGT Mfg) or Eurofins CDMO?
Both Bristol Myers Squibb (CGT Mfg) and Eurofins CDMO are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 91/100 and Eurofins CDMO carries 82/100 — a small lead for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →